#30: TheMachine: BioDelivery Sciences to Present at the ROTH Capital Partners 20th Annual Orange County Growth Stock Conference on February 20, 2008
Presentation to address BDSI’s lead
product, BEMATM Fentanyl,... |
February 18, 2008
05:31:43 AM |
#29: TheMachine: BioDelivery Sciences to Present BEMA(TM) Fentanyl Data at the 24th Annual Meeting of the American Academy of Pain Medicine
Study Shows That BEMA™ Fentanyl Provides
Rapid Absorption and... |
February 18, 2008
05:31:26 AM |
#28: TheMachine: BioDelivery Sciences and Meda to Expand Clinical Development Program for BEMA(TM) Fentanyl
Development of BEMATM Fentanyl
to be broadened beyond... |
February 18, 2008
05:31:02 AM |
#27: TheMachine: FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
If approved, BEMA™ Fentanyl will be the
next entry into the... |
February 18, 2008
05:30:34 AM |
#26: TheMachine: BioDelivery Sciences Appoints FD Ashton Partners As Its Strategic Communications Firm
BioDelivery Sciences International, Inc. (Nasdaq:... |
February 18, 2008
05:30:11 AM |
#25: NewsBot: BDSI News BDSI to Present on BEMA(TM) Fentanyl at American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting
MORRISVILLE, N.C.--(BUSINESS WIRE)--Dr. Andrew Finn, Executive Vice President of... |
March 21, 2007
08:10:00 AM |
#24: NewsBot: BDSI News BDSI to Present on BEMA(TM) Fentanyl at Oppenheimer Pain Conference
MORRISVILLE, N.C.--(BUSINESS WIRE)--Dr. Mark A. Sirgo, President and Chief... |
March 2, 2007
05:33:00 AM |
#23: NewsBot: BDSI News Hopkins Capital Group II Converts BDSI Series B Preferred Stock at $4.25 per Share
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc.... |
January 12, 2007
05:38:00 AM |
#22: NewsBot: BDSI News BDSI to Present at The PIPEs Conference 2006 at the Waldorf Astoria, New York City, November 7-8, 2006
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International,... |
November 6, 2006
04:00:00 AM |
#21: NewsBot: BDSI News BDSI Receives Approval to Restart BEMA(TM) Fentanyl Trials in California
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc.... |
September 26, 2006
08:55:00 AM |
#20: NewsBot: BDSI News Following FDA Meeting BDSI Projects Submission of BEMA(TM) Fentanyl NDA In Second Quarter 2007
MORRISVILLE, N.C.--(BUSINESS WIRE)--Sept. 20, 2006--BioDelivery Sciences... |
September 20, 2006
05:45:00 AM |
#19: NewsBot: BDSI News BioDelivery Sciences Claims Recent Actions by Clinical Development Capital Undermine All Other Stockholders' Interests
MORRISVILLE, N.C.--(BUSINESS WIRE)--Sept. 5, 2006-- Company Claims its... |
September 5, 2006
06:29:00 AM |
#18: NewsBot: BDSI News BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors; Former Glaxo U.S. President Brings Significant Drug Commercialization and Public Company Experience To BDSI
MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 30, 2006--BioDelivery Sciences... |
August 30, 2006
05:45:00 AM |
#17: NewsBot: BDSI News BioDelivery Sciences Mourns the Loss of Revered Board Member Bill Stephenson
MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 29, 2006--BioDelivery Sciences... |
August 29, 2006
05:45:00 AM |
#16: NewsBot: BDSI News BEMA(TM) LA Achieves Therapeutic Plasma Concentrations in Phase I Trial: Complementary Pain Therapy to Phase III BEMA(TM) Fentanyl Product
MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 16, 2006--BioDelivery Sciences... |
August 16, 2006
05:45:00 AM |
| 
| 
| 
| 
| 
| 
